ロード中...
Carfilzomib reverses pulmonary arterial hypertension
AIMS: Pulmonary arterial hypertension (PAH) remains a lethal disease with pronounced narrowing of pulmonary vessels due to abnormal cell growth. Agents that can reduce the pulmonary vascular thickness thus have therapeutic potential. The present study investigated the efficacy of carfilzomib (CFZ),...
保存先:
| 出版年: | Cardiovasc Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4836627/ https://ncbi.nlm.nih.gov/pubmed/26952044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvw047 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|